NATOLI, Clara
 Distribuzione geografica
Continente #
NA - Nord America 7.237
EU - Europa 5.713
AS - Asia 3.897
SA - Sud America 434
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 4
Totale 17.340
Nazione #
US - Stati Uniti d'America 7.186
SG - Singapore 1.575
CN - Cina 1.298
IE - Irlanda 1.016
UA - Ucraina 906
IT - Italia 772
SE - Svezia 765
FR - Francia 702
TR - Turchia 622
GB - Regno Unito 573
DE - Germania 448
BR - Brasile 388
IN - India 183
FI - Finlandia 164
RU - Federazione Russa 141
VN - Vietnam 85
AT - Austria 55
BE - Belgio 49
HK - Hong Kong 38
CA - Canada 32
CZ - Repubblica Ceca 30
PL - Polonia 19
EU - Europa 17
BD - Bangladesh 16
NL - Olanda 15
AR - Argentina 12
RO - Romania 10
IQ - Iraq 9
UZ - Uzbekistan 9
EG - Egitto 8
ES - Italia 8
IL - Israele 8
JP - Giappone 8
MX - Messico 8
MA - Marocco 7
AE - Emirati Arabi Uniti 6
EC - Ecuador 6
LT - Lituania 6
UY - Uruguay 6
VE - Venezuela 6
AL - Albania 5
ID - Indonesia 5
PK - Pakistan 5
SA - Arabia Saudita 5
ZA - Sudafrica 5
AU - Australia 4
BO - Bolivia 4
CH - Svizzera 4
CO - Colombia 4
DK - Danimarca 4
DZ - Algeria 4
GR - Grecia 4
CL - Cile 3
HR - Croazia 3
JO - Giordania 3
KE - Kenya 3
KG - Kirghizistan 3
MT - Malta 3
PY - Paraguay 3
SN - Senegal 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AZ - Azerbaigian 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
IR - Iran 2
JM - Giamaica 2
LB - Libano 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EE - Estonia 1
ET - Etiopia 1
HN - Honduras 1
HU - Ungheria 1
KW - Kuwait 1
LU - Lussemburgo 1
MK - Macedonia 1
NG - Nigeria 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 17.340
Città #
Chandler 1.479
Jacksonville 1.167
Singapore 1.132
Dublin 1.007
Princeton 466
Southend 414
Izmir 376
Nanjing 342
Ashburn 279
Wilmington 224
Beijing 212
The Dalles 195
Dearborn 189
Ann Arbor 177
Cambridge 174
Altamura 167
Santa Clara 157
Boardman 148
Chieti 138
Nanchang 125
Tongling 111
Munich 103
Los Angeles 95
Woodbridge 93
New York 85
Houston 80
Dong Ket 68
Shenyang 63
Hebei 60
Kunming 54
Tianjin 51
Brussels 47
Washington 43
Vienna 42
Jiaxing 40
Norwalk 37
Hong Kong 36
São Paulo 36
Rome 32
Nuremberg 29
Pescara 29
Helsinki 26
Changsha 23
Chicago 23
Brno 22
Falls Church 22
Seattle 22
Hangzhou 20
Milan 20
Kocaeli 19
San Mateo 17
Brooklyn 16
Lanzhou 16
London 16
Rio de Janeiro 15
Turku 15
Auburn Hills 14
Tappahannock 14
Belo Horizonte 13
Changchun 13
Guangzhou 13
Augusta 12
Boston 12
Düsseldorf 12
Frankfurt am Main 12
Grevenbroich 12
Shanghai 12
Ningbo 11
San Francisco 11
Edinburgh 10
Frontone 10
Toronto 10
Campinas 9
Jinan 9
Leawood 9
Mumbai 9
Tashkent 9
Warsaw 9
Zhengzhou 9
Cairo 8
Fairfield 8
Giaveno 8
Moscow 8
Aprilia 7
Dallas 7
Hefei 7
Pune 7
Tokyo 7
Amsterdam 6
Atlanta 6
Collecorvino 6
Franca 6
Giulianova 6
Guarulhos 6
Menlo Park 6
Orange 6
Romola 6
Secaucus 6
Bristol 5
Charlotte 5
Totale 10.485
Nome #
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 151
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 146
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 129
A multidisciplinary group for prostate cancer management: A single institution experience 127
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 124
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 123
New Targets for Therapy in Pancreatic Cancer 121
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 119
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 115
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 115
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 115
90K (Mac-2 BP) in human milk 114
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 114
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 113
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 111
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 110
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 108
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 108
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 107
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 107
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 107
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 107
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 106
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 105
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 104
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 103
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 102
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 102
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 102
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 101
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 101
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 101
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 101
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 101
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 100
Surgical treatment of adrenal metastases from non small cell lung cancer 100
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 99
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 99
Chemotherapy preoperative for the management of breast cancer locally advanced 99
DNA ploidy and S-phase fraction in pulmonary carcinoids. 99
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 99
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 98
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 98
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 97
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 97
Tyrosine kinase inhibitors 96
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 95
Principali effetti collaterali delle terapie mediche 95
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 95
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 94
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 94
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 94
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 94
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 93
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 93
Unknown primary tumors 92
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 92
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 92
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 91
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 91
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 91
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 91
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 90
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 90
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 90
A Flow cytometric study of early gastric cancer 89
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 89
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 88
Tumor-derived microvesicles: The metastasomes. 88
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 88
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 88
Prognostic value of 90K protein in HIV infection 87
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 87
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 87
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 87
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 87
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 87
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies 86
Interleukin-30 Promotes Breast Cancer Growth and Progression 86
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 86
La stimolazione dinamica con IFN-α per la diagnosi precoce di ripresa di malattia in pazienti NED 85
Prognostic value of a novel circulating serum 90K antigen in breast cancer 85
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 85
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 85
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 85
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 85
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 84
Circadian timing of chemotherapeutic agents:a phase II study of 5-fluoro-2-deoxyuridine in gastrointestinal cancer and renal cell carcinoma 83
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 83
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 83
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 83
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 83
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 83
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 82
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 82
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 82
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 81
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 81
Combinations of biological response modifiers: rationale and clinical responses. 81
Rivaroxaban for cancer-associated cardiac thrombosis 81
Totale 9.730
Categoria #
all - tutte 74.490
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.490


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.456 228 22 278 12 90 287 34 43 97 151 84 130
2021/20221.092 23 33 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20253.673 202 692 532 115 86 173 137 218 355 188 418 557
2025/2026281 281 0 0 0 0 0 0 0 0 0 0 0
Totale 18.185